{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:48:04Z","timestamp":1790196484135,"version":"4.1.0"},"reference-count":45,"publisher":"Bioscientifica","issue":"6","funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["D15D18000410001"],"award-info":[{"award-number":["D15D18000410001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pontificia Universidad Javeriana. Apoyo a proyectos de tesis doctorales Corte 2","award":["ID 28821"],"award-info":[{"award-number":["ID 28821"]}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple negative breast cancer (TNBC) is a heterogeneous disease, considered the most aggressive among all diagnosed breast cancers. The luminal androgen receptor (LAR) category has been recognized as a distinct entity (subtype), observed in around 15% of the TNBCs, but currently there is no complete overlap to clearly distinguish them from the other TNBC counterparts. With the aim to better establish morphological, immunohistochemical and molecular features of LAR tumors, gene and signatures expression was evaluated in 42 well-characterized TNBCs. Furthermore, protein expression of a panel of several markers (AR, FOXA1, CK5\/6, p63, GCDFP-15 and FGFR4) was also studied. Compared with non-LAR cases, LAR tumors often display low tumor grade, reduced levels of Ki-67, total absence of CK5\/6 and p63 basal markers expression, but show high positivity for AR, FOXA1 and FGFR4. Regarding molecular assessment, LAR tumors were characterized by higher scores of gene signatures associated with AR, FOXA1 and ERBB2, while showed lower scores of signatures related to BC proliferation, CDK6, BRCAness and p53. Our results suggest that among TNBC, LAR cases are associated with features indicative of a less aggressive tumor behavior. Accurate distinction of this TNBC subtype is important since they are resistant to chemotherapy and may potentially benefit from tailored-therapeutical approaches. Specifically, therapies targeting AR together to additional proteins, such as FGFR4, FOXA1 or CDK6, may represent future directions in the treatment approach of LAR tumors.<\/jats:p>","DOI":"10.1530\/erc-24-0316","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:04:57Z","timestamp":1745391897000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":5,"title":["Surrogate molecular classification of LAR breast cancer in routine workflow"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-2196","authenticated-orcid":true,"given":"Nelson","family":"Rangel","sequence":"first","affiliation":[{"name":"Departamento de Nutrici\u00f3n y Bioqu\u00edmica, Facultad de Ciencias, Pontificia Universidad Javeriana 1 , ,","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Serrao","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin 2 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Capella","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin 2 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin 3 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ragno","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin 2 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-9316","authenticated-orcid":true,"given":"Milena","family":"Rond\u00f3n-Lagos","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Universidad Pedag\u00f3gica y Tecnol\u00f3gica de Colombia 4 , ,","place":["Tunja, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Metovic","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital 5 , , ,","place":["Boston, Massachusetts, USA"]},{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School 6 , , ,","place":["Boston, Massachusetts, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin 2 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin 2 , ,","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2026070905450712500_bib1","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070905450712500_bib2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070905450712500_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4132\/KoreanJPathol.2012.46.2.169","article-title":"The clinicopathologic features of molecular apocrine breast cancer","volume":"46","author":"Cha","year":"2012","journal-title":"Korean J Pathol"},{"key":"2026070905450712500_bib4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies-improving the management of early breast cancer: st gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"2026070905450712500_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-018-0933-y","article-title":"HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors","volume":"20","author":"Daemen","year":"2018","journal-title":"Breast Cancer Res"},{"key":"2026070905450712500_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front Endocrinol"},{"key":"2026070905450712500_bib7","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1038\/s41598-019-41016-4","article-title":"Androgens induce invasiveness of triple negative breast cancer cells through AR\/Src\/PI3-K complex assembly","volume":"9","author":"Giovannelli","year":"2019","journal-title":"Sci Rep"},{"key":"2026070905450712500_bib8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"2026070905450712500_bib9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"2026070905450712500_bib10","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026070905450712500_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000519255","article-title":"Identifying high-risk triple-negative breast cancer patients by molecular subtyping","volume":"16","author":"Hartung","year":"2021","journal-title":"Breast Care"},{"key":"2026070905450712500_bib12","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol Endocrinol"},{"key":"2026070905450712500_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/bjc.2015.464","article-title":"Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-\u03b1-negative breast cancer","volume":"114","author":"Hilborn","year":"2016","journal-title":"Br J Cancer"},{"key":"2026070905450712500_bib14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070905450712500_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100403","article-title":"Novel 2 gene signatures associated with breast cancer proliferation: insights from predictive differential gene expression analysis","volume":"37","author":"Ibrahim","year":"2024","journal-title":"Mod Pathol"},{"key":"2026070905450712500_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070905450712500_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/cancers15010233","article-title":"Anti-androgenic therapies targeting the luminal androgen receptor of a typical triple-negative breast cancer","volume":"15","author":"Khadela","year":"2022","journal-title":"Cancers"},{"key":"2026070905450712500_bib18","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"2026070905450712500_bib19","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.14694\/EdBook_AM.2015.35.e31","article-title":"Triple-negative breast cancer: molecular subtypes and new targets for therapy","volume":"35","author":"Lehmann","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070905450712500_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"2026070905450712500_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3421","article-title":"Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15","volume":"15","author":"Lehmann-Che","year":"2013","journal-title":"Breast Cancer Res"},{"key":"2026070905450712500_bib22","first-page":"1910","article-title":"Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer","volume":"25","author":"Di Leone","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026070905450712500_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107590","article-title":"FGFR4: a promising therapeutic target for breast cancer and other solid tumors","volume":"214","author":"Levine","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2026070905450712500_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/njcp.njcp_437_20","article-title":"Triple-negative breast cancer (TNBC) and its luminal androgen receptor (LAR) subtype: a clinicopathologic review of cases in a university hospital in Northwestern Nigeria","volume":"25","author":"Liman","year":"2022","journal-title":"Niger J Clin Pract"},{"key":"2026070905450712500_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cjp2.149","article-title":"\u2206Np63\/p40 correlates with the location and phenotype of basal\/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers","volume":"6","author":"Liu","year":"2020","journal-title":"J Pathol Clin Res"},{"key":"2026070905450712500_bib26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/annonc\/mdg197","article-title":"Prognostic value of p53 molecular status in high-risk primary breast cancer","volume":"14","author":"Marchetti","year":"2003","journal-title":"Ann Oncol"},{"key":"2026070905450712500_bib27","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026070905450712500_bib28","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1158\/0008-5472.CAN-05-0912","article-title":"Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action","volume":"65","author":"Migliaccio","year":"2005","journal-title":"Cancer Res"},{"key":"2026070905450712500_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor\u2013positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2026070905450712500_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.31557\/APJCP.2020.21.2.563","article-title":"Neoadjuvant chemotherapy in triple negative breast cancer: correlation between androgen receptor expression and pathological response","volume":"21","author":"Mohammed","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026070905450712500_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African\u2013American and Caucasian patients","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"2026070905450712500_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","article-title":"Molecular characterization of basal-like and non-basal-like triple-negative breast cancer","volume":"18","author":"Prat","year":"2013","journal-title":"Oncologist"},{"key":"2026070905450712500_bib33","first-page":"186","article-title":"Role of the androgen receptor in triple-negative breast cancer","volume":"14","author":"Rampurwala","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"2026070905450712500_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12885-018-4624-y","article-title":"FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients","volume":"18","author":"Rangel","year":"2018","journal-title":"BMC Cancer"},{"key":"2026070905450712500_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00428-006-0233-2","article-title":"Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure","volume":"449","author":"Sapino","year":"2006","journal-title":"Virchows Arch"},{"key":"2026070905450712500_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/OTT.S379867","article-title":"Potential therapeutic targets for luminal androgen receptor breast cancer: what we know so far","volume":"16","author":"Stella","year":"2023","journal-title":"OncoTargets Ther"},{"key":"2026070905450712500_bib37","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026070905450712500_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac018","article-title":"Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response","volume":"4","author":"Thompson","year":"2022","journal-title":"NAR Cancer"},{"key":"2026070905450712500_bib39","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070905450712500_bib40","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D\u2013CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070905450712500_bib41","first-page":"1393","article-title":"Apocrine carcinoma of the breast: a comprehensive review","volume":"28","author":"Vranic","year":"2013","journal-title":"Histol Histopathol"},{"key":"2026070905450712500_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1631\/jzus.B2200113","article-title":"Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features","volume":"23","author":"Vtorushin","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"2026070905450712500_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"Npj Breast Cancer"},{"key":"2026070905450712500_bib44","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"},{"key":"2026070905450712500_bib45","doi-asserted-by":"crossref","first-page":"70113","DOI":"10.18632\/oncotarget.12158","article-title":"BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/6\/ERC-24-0316.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/6\/ERC-24-0316.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0316\/247035\/erc-24-0316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0316\/247035\/erc-24-0316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:45:20Z","timestamp":1783590320000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/6\/e240316\/25959\/Surrogate-molecular-classification-of-LAR-breast"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0316","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"article-number":"e240316"}}